Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04385160 · ClinicalTrials.gov registry record
Myeloproliferative Neoplasms (MPN) and COVID-19
A clinical trial, sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS.
- Completed
- Registry status
- 552
- Enrollment target
NCT04385160: Completed study, sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS.
NCT04385160 is a clinical trial that has completed, run by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The registered enrollment target is 552 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04385160 has completed, sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS.
- COMPLETED
- Registry status
- 552 participants
- Enrollment target
Study Summary
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
Primary Outcome
Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2022-08-31 |
What the finished NCT04385160 record still lists
NCT04385160 is an observational study that tracks outcomes without assigning an intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04385160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04385160 about?
NCT04385160 is a clinical study titled "Myeloproliferative Neoplasms (MPN) and COVID-19". An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential throm...
What is the current status of trial NCT04385160?
This trial is currently completed. The enrollment target is 552 participants. The study started on 2020-05-13. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT04385160?
This trial is sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI